Arthritis is a recognised manifestation of Behçet's syndrome and defines a specific clinical sub-population requiring a focused therapeutic approach. This page summarises the key considerations for this scenario.
This protocol applies to patients with Behçet's syndrome in whom arthritis is the presenting or predominant feature. Joint involvement — whether isolated to a single joint or more widespread — directly informs the selection and sequencing of treatment.
Management in this setting begins with an established oral agent recommended as initial therapy for arthritis in Behçet's syndrome. For acute disease confined to a single joint, a targeted local intervention is also an option.
DOI: 10.1136/annrheumdis-2018-213225
Colchicine should be the initial treatment in BS patients with acute arthritis.
Acute monoarticular disease can be treated with intra-articular glucocorticoids.
View source ↗